Popular topics to explore
20 mins ago · SEBI Registration INH000022136
SEBI Registration INH000022136 · 20 mins ago
Investor Update: Dr. Reddy's Laboratories Ltd.
DRREDDY
Regulatory Update: Mexico API Facility
Dr. Reddy's Laboratories announced the conclusion of a USFDA records assessment at its active pharmaceutical ingredient (API) manufacturing facility in Jiutepec, Mexico (Industrias Químicas F…
Dr. Reddy’s Laboratories – Latest Fundamental Update
DRREDDY Dr. Reddy’s Laboratories (DRREDDY) reported a weak Q1 FY27 on a YoY basis. Consolidated revenue declined 5.6% to ₹8,071 crore, while PAT fell sharply by about 69% to ₹444 crore. EBITDA declined 55.7% to ₹1,009 crore and margin co…
Nifty Pharma | The Only Sector That Ended Green on Sept 7
Sector performance, Monday September 7, 2026: Nifty IT: declined. Nifty Metal: declined. Nifty PSU Bank: declined. Nifty Media: declined. Nifty Auto: declined. Nifty FMCG: declined. Nifty Private Bank: declined. Nifty Realty: declined. Nif…
Dr Reddy’s: Pharma Growth Beyond Legacy Products
DRREDDY Dr. Reddy’s Laboratories is a diversified global pharma company with strong exposure to generics, APIs, biosimilars and innovative therapies. Q1 FY27 revenue declined 5.6% YoY to ₹8,071 crore, while PAT fell 69% to ₹443.5 crore, ma…
Close crossing last Month High Strategy.............
Close crossing last Month High Strategy
DRREDDY is trading near its previous month high.
• This strategy focuses on stocks that close above the previous month’s high, which often signals fresh momentum and strong buying interest.
• A…
Dr Reddy's - Bearish, Falling MA and below crucial support
DRREDDY is showing a bearish setup as both the fast and slow moving averages are falling, confirming weakening momentum. Price has also broken below a key support zone, opening the possibility of further downside. The trend remains weak…
“Index पर दबाव हो सकता है, लेकिन अवसर खत्म नहीं होते—बस ध्यान सही Share और सही स्तरों पर होना चाहिए।”
आज का Market Outlook / Closing View Nifty: 24,287.65, -78 points (-0.32%) Sensex: 77,728, -281 points (-0.36%) Nifty ne 5th consecutive session decline diya. Main pressure elevated crude oil, Middle-East/U.S.-Iran tensions, IT selling aur F…
Dr. Reddy’s Laboratories – Pharma Watch
DRREDDY
Important Levels:
Support: ₹1,170 – ₹1,140
Resistance: ₹1,230 – ₹1,260
Structure: Recovery attempt after a prolonged correction
Business:
Global pharmaceutical company with exposure to generics, APIs, biosimilars and differenti…
15th Aug · SEBI Registration INH000020466
SEBI Registration INH000020466 · 15th Aug
Dr. Reddy’s Laboratories Receives Mixed USFDA Inspection Updates: Form 483 in Hyderabad, Favorable VAI in UK
Dr. Reddy’s Laboratories Limited has provided updates on two recent Good Manufacturing Practices (GMP) inspections conducted by the United States Food & Drug Administration (USFDA) at its global facilities, reflecting a mix of routine regul…
Nifty Outlook for 12-Aug-2026
The overall trend of Nifty looks to be in a range, and thus the markets might move either side. Buy on dips and sell on rise would be the best strategy to deploy for today’s market considering the overall trend of Nifty. We may expect a c…
11th Aug · SEBI Registration INH000020350
SEBI Registration INH000020350 · 11th Aug
Technical View Dr. Reddy’s Laboratories
The stock DRREDDY is showing a short-term recovery after a sharp correction from the ₹1380–1400 zone. Price has bounced from around ₹1110–1120 and is now making a gradual recovery indicating buying interest at lower levels. However the br…
Morning Market Edge-----> Nifty Holds Above 24,500, But 24,700 Remains the Biggest Hurdle! Will Bulls Finally Break Through Today?
Indian markets are expected to open on a cautious note today. While US markets ended slightly lower, crude oil remains stable, and FII positioning continues to stay broadly constructive, Nifty has now spent three consecutive sessions strug…
DRREDDY
technical signals reinforce the cautious outlook. The daily moving averages have turned bearish, aligning with the Death Cross formation. Weekly and monthly MACD readings suggest bearish to mildly bearish momentum, while Bollinger Bands on…
Pharma Stocks Surge After Strong Q1 Earnings Boost Sector Sentiment
The pharmaceutical sector remained in focus after several drug manufacturers reported strong Q1 FY27 earnings, supported by healthy domestic demand, robust export sales, and improved operating margins. Stocks such as Navin Fluorine and Neul…
NEW LAUNCH----> Why This US Drug Launch Matters More Than You Think.
DRREDDY has announced the first-to-market launch of Sugammadex Injection (200 mg/2 mL and 500 mg/5 mL) in the United States, a generic equivalent of Merck's Bridion®.
For investors, this is more than just another generic launch—it repres…
HAL
**Defence Order Book & US Launch**
** HAL :** Reported a **robust order book of ₹2,54,538 crore** as of March 31, 2026, including major contracts for **97 LCA Mk1A fighters, 6 ALH MkIII MR helicopters and 2 Do-228 aircraft**. The company…
Market outlook for today (Tuesday, August 4, 2026) TRENT DRREDDY
Market outlook for today (Tuesday, August 4, 2026) Overall sentiment is cautiously bullish. Global markets Asian equities are trading mostly higher after a strong overnight session on Wall Street. Investor sentiment has improved as geopo…
DRREDDY
**USFDA Approvals & Major Order Win**
** DRREDDY :** Received **US FDA approval** for its **Rituximab biosimilar** for the U.S. market, used to treat blood cancers and autoimmune diseases.
**Impact:** **Positive;** strengthens the biosi…
FII UPDATE-----> Foreign Investors Are Back! After 4 Months of Selling, FPIs Return With ₹20,200 Crore. Is This the Start of a New Rally?
After four consecutive months of net selling, Foreign Portfolio Investors (FPIs) turned net buyers in July, investing nearly ₹20,200 crore into Indian equities. The reversal comes as improving macroeconomic conditions, easing global concern…
Q1 Earnings Snapshot:-----> DIVISLAB & MUTHOOTFIN Deliver Strong Numbers. Here's What you Need to Know.
Two quality companies from different sectors reported impressive Q1 results, with both posting robust growth in revenue and profitability.
Here's a quick snapshot:
Q1 Results : DIVISLAB Net Profit Rises 65.5%
Divi's Laboratories Q1 Resu…
